Tonix Pharmaceuticals Holding Corp. TNXP ("Tonix"), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache, announced today that three of its scientific abstracts have been accepted for presentation at the 2015 American College of Rheumatology / Association of Rheumatology Health Professionals Annual Meeting to be held November 7-11, 2015, in San Francisco, CA.
The abstract and presentation details are as follows:
Title:
"Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL)."
Authors: Harvey Moldofsky, R Michael Gendreau, Daniel J. Clauw, Judith Gendreau, Benjamin Vaughn, Bruce Daugherty, Amy Forst, Gregory Sullivan and Seth Lederman
Date & Time: Tuesday, November 10, 2015, 9:00 – 11:00 am
Location: ACR Poster Session C
Number: 2307
Title:
"Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL)."
Authors: R Michael Gendreau, Daniel J. Clauw, Judith Gendreau, Bruce Daugherty and Seth Lederman
Date & Time: Tuesday, November 10, 2015, 9:00 – 11:00 am
Location: ACR Poster Session C
Number: 2308
Title:
"Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study."
Authors: Seth Lederman, R Michael Gendreau, Daniel J. Clauw, Lesley M. Arnold, Judith Gendreau, Bruce Daugherty and Amy Forst
Date & Time: Tuesday, November 10, 2015, 9:00 – 11:00 am
Location: ACR Poster Session C
Number: 2309
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in